MTHFR and type 2 diabetes mellitus: In Canadian Oji-Cree subjects with type 2 diabetes, we found that: 1) MTHFR 677T carriers had an increased risk of PAD [OR 3.54 (1.01, 12.4), P = 0.049], adjusting for age, sex, duration of diabetes, hypertension, current smoking habits, and diabetes treatment; and 2) there was no significant association between MTHFR genotype and intermittent claudication, a much more advanced stage of PAD.